<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437865</url>
  </required_header>
  <id_info>
    <org_study_id>11-2-016</org_study_id>
    <nct_id>NCT01437865</nct_id>
  </id_info>
  <brief_title>Gadofosveset for Axillary Staging in Breast Cancer Patients</brief_title>
  <official_title>Non-invasive Nodal Staging in Breast Cancer With MRI Lymphography Using Gadofosveset; a Pilot-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot-study is to examine the accuracy of gadofosveset enhanced MRI compared
      to current nodal staging methods.

      The accuracy of MRL will be determined on the basis of a node-to-node matching of imaged
      nodes to the definitive histopathology. The pathologic examination of the SNLB or ALND will
      be regarded as the golden standard for nodal involvement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The accuracy (sensitivity, specificity, NPV and PPV) of the MRI in predicting the involvement of metastases</measure>
    <time_frame>Participants will be followed from the moment of first out-hospital clinic vistit untill final breast surgery, an expected average of 4 weeks.</time_frame>
    <description>The main study parameter will be the accuracy (sensitivity, specificity, NPV and PPV) of the MRI in predicting the involvement of metastases in the investigated lymph nodes. Each node will be scored on MRI as 0= benign, 1=malign. These results will be compared with the histopathological results of the SNLB procedure of ALND procedure on an node by node basis. So the accuray can be calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Gadofosveset enhanced MRI Axilla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadofosveset contrast agent enhanced MRI Axilla</intervention_name>
    <description>A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.</description>
    <arm_group_label>Gadofosveset enhanced MRI Axilla</arm_group_label>
    <other_name>Gadofosveset (Ablavar/Vasovist) EMEA/H/C/000601</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with histopathologically confirmed invasive breast cancer about to undergo
             nodal staging.

          2. Tumor must be a T2 according the TNM 6-classification.

          3. The ultrasound of the axilla must be suspect for nodal metastases.

          4. Willing and able to undergo all study procedures

          5. Has personally provided written informed consent.

        Exclusion Criteria:

          1. Age &lt;18

          2. History of prior chemotherapy

          3. History of prior radiotherapy of the surrounding areas of the axilla.

          4. Pregnancy

          5. Contra indications for MRI such as pacemaker, aneurysm clips or severe claustrophobia.

          6. Allergy to any of the ingredients of Gadofosveset (Vasovist® /Ablavar®)

          7. Being unable to give informed consent in person

          8. Acute or chronic severe renal insufficiency (glomerular filtration rate &lt;30
             mL/min/1.73m2).

          9. Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the
             perioperative liver transplantation period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Beets - Tan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center (MUMC) AZM</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>lymph node metastases</keyword>
  <keyword>breast cancer</keyword>
  <keyword>gadofosveset</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

